Bcel stock forecast.

11.30% of Atreca stock is owned by insiders. Which Atreca insiders have been selling company stock? The following insiders have sold BCEL shares in the last 24 months: Bros. Advisors Lp Baker ($109,895.60), John A Orwin ($37,216.24), Phillips Courtney ($15,321.16), and Tito Serafini ($199,122.53).🚀 Atreca stock price forecast: $4; Market Cap: 11.00M, Enterprise value: 68.43M, P/E: -0.4, PEG ratio: -0.03, EPS: -2.11, Revenue: N/A, EBITDA: -81.73M, Income ...Stock Analyst Price Targets - Review. Analysts average stock forecasts to be materialized ratio is 4.17% with an average time for these price targets to be met of 0.17 days. Highest price target for BCEL is 5, Lowest price target is 1, average price target is 3. Most recent stock forecast was given by ROBERT DRISCOLL from WEDBUSH on 14 …Atreca Inc [BCEL] stock prices are down -14.82% to $0.28 at the moment. ... An investor can expect a potential return of 1060.71% based on the average BCEL price forecast. Analyzing the BCEL fundamentals. In this publicly-traded organization, revenue per employee is $8,556, ...Find real-time KR - Kroger Co stock quotes, company profile, news and forecasts from CNN Business.

Nov 23, 2023 · Science. Atreca Inc (NASDAQ:BCEL)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 1.24. At the close of trading, the stock’s price was $0.21. The BCEL share’s 52-week high remains $2.05, putting it -876.19% down since that peak but still an impressive 9.52% since price per share fell ... BCEL vs Biotech Stocks. Ticker Inst. % Insider % Net Insider (L12M) Net Insider (L3M) BCEL: 31.32%: 21.52%: Net Selling: Net Selling: IMNN: 4.39%: 92.03%: FRES: 0.00%: 0.00%: ... Top Performing Analysts Stock Screener Stock Forecast Trending Stocks Strong Buy Stocks Highest Earnings Stocks Best Dividend Paying Stocks Statistics …

Atreca, Inc. (BCEL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...Atreca, Inc. (BCEL.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Atreca, Inc. | Nasdaq: BCEL | Nasdaq

BCEL is currently rated as a Sucker Stock | Stockopedia. Login Get Started. Sectors Healthcare Biotechnology & Medical Research Atreca. ... Is there a Atreca share price forecast for 2023? The analyst consensus target price for shares in Atreca is $3.25. That is 1420.11% above the last closing price of $0.21.May 6, 2023 · Atreca Stock Forecast and Price Target. According to six esteemed experts, the average price target for Atreca to reach this year is $17.00, with a potential upside of approximately 1,600%. This prediction is based on a high estimate of $35.00 and a low estimate of $11.00. Stock Price Forecast. The 31 analysts offering 12-month price forecasts for Li Auto Inc have a median target of 51.77, with a high estimate of 81.63 and a low estimate of 35.76. The median ...Stock Price Forecast. According to 4 stock analysts, the average 12-month stock price forecast for Atreca stock is $3.38, which predicts an increase of 1,472.09%. The lowest target is $1.00 and the highest is $10. On average, analysts rate Atreca stock as a hold.

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Cymabay Therapeutics share forecasts, stock quote and buy / sell signals below. According to present data Cymabay Therapeutics's CBAY shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).

Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...

BCEL Stock Predictions, Articles, and Atreca Inc Cl A News From InvestorPlace From the Web 3 Penny Stocks to Catapult You Into the Millionaires’ Club By Omor Ibne Ehsan Jul 13, 2023 ...Stock Price Forecast. The 8 analysts offering 12-month price forecasts for EyePoint Pharmaceuticals Inc have a median target of 28.00, with a high estimate of 55.00 and a low estimate of 20.00 ...Nov 6, 2023 · Analyst projections state that BCEL is forecast to be at a low of $1.00 and a high of $9.00. In order for the stock price to hit the forecast high, the stock would need to plunge -3361.54% from its current level, while the stock would need to crash -284.62% from its current level to reach the projected low. Atreca Inc (BCEL) estimates and forecasts Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...As the old saying goes, “Forewarned is forearmed.” This sentiment holds true when it comes to weather forecasting as well. One of the primary advantages of a 30-day extended weather forecast is the ability to plan ahead with confidence.The average Adma Biologics stock price prediction forecasts a potential upside of 43.11% from the current ADMA share price of $3.96. What is ADMA's forecast return on equity (ROE) for 2023-2026? (NASDAQ: ADMA) forecast ROE is N/A, which is considered weak.

BCEL stock forecast Our latest prediction for Atreca Inc's stock price was made on the Aug. 7, 2023 when the stock price was at 0.91$. In the short term (2weeks), BCEL's stock price should underperform the market by -3.07%. During that period the price should oscillate between -9.61% and +7.63%.How much is Atreca stock worth today? ( NASDAQ: BCEL) Atreca currently has 39,295,661 outstanding shares. With Atreca stock trading at $0.27 per share, the total value of Atreca stock (market capitalization) is $10.41M. Atreca stock was originally listed at a price of $18.05 in Jun 20, 2019.October 13, 2023. At the time of writing, Atreca Inc [BCEL] stock is trading at $0.38, up 61.06%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCEL shares have gain 66.93% over the last week, with a monthly amount glided 11.79%, and seem to be holding up well over a long-time horizon.A list of analyst ratings for Atreca (BCEL) stock. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. ... Forecast; Analyst Ratings; BCEL's stock price has decreased by -82.11% in the past year and price targets may not have had time to catch up.Analyst Ratings of ATRECA INC - A(NASDAQ:BCEL) stock. Analyst ratings, forecast, price target, upgrades and ... Analysts have set a mean price target forecast of 3.32. This target is 1406.82 ... seem to be have mildly positive about BCEL. In the previous month the buy percentage consensus was at a similar level. BCEL was analyzed by 13 analysts ...

Find the latest W&T Offshore, Inc. (WTI) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid ...

Analyst Forecast. According to 5 analysts, the average rating for BCEL stock is "Hold." The 12-month stock price forecast is $3.38, which is an increase of 1,479.44% from the latest price.Tecnoglass Inc () Stock Market info Recommendations: Buy or sell Tecnoglass stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Tecnoglass share forecasts, stock quote and buy / sell signals below.According to present data Tecnoglass's TGLS shares and potentially its market environment have been in a bullish …Cymabay Therapeutics Inc () Stock Market info Recommendations: Buy or sell Cymabay Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Cymabay Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Cymabay Therapeutics's CBAY shares and potentially …$0.220 +0.0047 (+2.19%) At Close: Nov 30, 2023 Real-time prices appear during market hours U.S. markets are closed | Score: -1.37 Strong Sell Hold Strong Buy …According to the issued ratings of 5 analysts in the last year, the consensus rating for Atreca stock is Hold based on the current 4 hold ratings and 1 buy rating for BCEL. The average twelve-month price prediction for Atreca is $10.75 with a high price target of $25.00 and a low price target of $4.00. Learn more on BCEL's analyst rating history.The rating of the stock has changed to hold according to some analysts. It's at an all time low, buy folks thanks me later. Recently BCEL has reached an all time low and a data suggests that is will rise back up. According to Fintel.IO Blackrock has bought a staggering 350k shares. The rating of the stock has changed to hold according to some ...Aug 14, 2023 · BCEL Earnings Date and Information. Atreca last posted its quarterly earnings data on May 10th, 2023. The reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.02. Atreca has generated ($2.18) earnings per share over the last year ( ($2.18) diluted earnings per share). 231.40. -1.20%. 108.31K. Find the latest Atreca Inc (BCEL) stock forecast, 12-month price target, predictions and analyst recommendations.

BANQUE POUR LE COMMERCE EXTERIEUR LAO PUBLIC. Date: Previous day: Opening : Last: Change: Change (%) High: Low: Trading Volume (shr) Trading Value (LAK)

Atreca Inc Cl A (BCEL) Company Description. Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism ...

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Viking Therapeutics share forecasts, stock quote and buy / sell signals below. According to present data Viking Therapeutics's VKTX shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).Find real-time VCEL - Vericel Corp stock quotes, company profile, news and forecasts from CNN Business.Shares in Artego SA last closed at RON15.30 and the price had moved by +23.39% over the past 365 days. In terms of relative price strength the Artego SA share price has outperformed the FTSE Global All Cap Index by +15.74% over the past year.Find the latest Patterson-UTI Energy, Inc. (PTEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Atreca Inc - Class A Stock Chart and Share Price Forecast, Short-Term "BCEL" Stock Prediction for Next Days and Weeks Walletinvestor.com Atreca Inc - Class A (BCEL) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Nov 1, 2023 · According to analyst projections, BCEL’s forecast low is $1.00 with $9.00 as the target high. To hit the forecast high, the stock’s price needs a -4185.71% plunge from its current level, while the stock would need to soar -376.19% for it to hit the projected low. Atreca Inc (BCEL) estimates and forecasts Hudbay Minerals Inc. () Stock Market info Recommendations: Buy or sell Hudbay Minerals stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Hudbay Minerals share forecasts, stock quote and buy / sell signals below.According to present data Hudbay Minerals's HBM shares and potentially its …Forecst.com predicts future values using technical analysis of a large number of analytical parameters. BCEL stock returns are also predicted based on historical data. According to our research, BCEL stock is a bad long-term investment. BCEL share price has been in a bear cycle for the past year. Atreca, Inc. stock trend is negative .5 equities research analysts have issued twelve-month target prices for Atreca's stock. Their BCEL share price targets range from $4.00 to $25.00. On average, they expect the company's stock price to reach $10.75 in the next twelve months. This suggests a possible upside of 4,474.5% from the stock's current price.

Atreca Inc - Class A Stock Chart and Share Price Forecast, Short-Term "BCEL" Stock Prediction for Next Days and Weeks Walletinvestor.com Atreca Inc - Class A (BCEL) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 Atreca stock forecast report. View BCEL price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data.DM Stock 12 Months Forecast. $1.00. (27.88% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Desktop Metal in the last 3 months. The average price target is $1.00 with a high forecast of $1.00 and a low forecast of $1.00. The average price target represents a 27.88% change from the last price of $0.78.Instagram:https://instagram. brrnno load index fundsmartasset advisor reviewsnso malpractice insurance reviews April 06, 2023 — 09:55 am EDT. Written by Zacks Equity Research for Zacks ->. Shares of Atreca, Inc. (BCEL) have been struggling lately and have lost 20% over the past week. However, a hammer ... buy oxyshaq shoes walmart Nov 30, 2023 · The Atreca Inc. stock price gained 5.36% on the last trading day (Friday, 17th Nov 2023), rising from $0.209 to $0.220. During the last trading day the stock fluctuated 9.33% from a day low at $0.210 to a day high of $0.230. The price has been going up and down for this period, and there has been a -16.59% loss for the last 2 weeks. The BCEL shares have gain 66.93% over the last week, with a monthly amount glided 11.79%, and seem to be holding At the time of writing, Atreca Inc [BCEL] stock is trading at $0.38, up 61.06%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. unusual stock option activity Nov 28, 2023 · A high-level overview of Atreca, Inc. (BCEL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN ...